EP
HOWL icon

Essential Partners’s Werewolf Therapeutics HOWL Stock Holding History

Essential Partners’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-52
Closed -$57 – 2721
2025
Q2 		$57 Buy
+52
New +$54 ﹤0.01% 2137

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's HOWL Position: Q3 2025 in Review

Essential Partners sold out of Werewolf Therapeutics (HOWL) in Q3 2025, closing a stake of 52 shares — an estimated $57 sold.

Essential Partners first reported a position in HOWL in Q2 2025 and held it in 1 quarter. The position peaked at $57 in Q2 2025. 62 funds tracked by Wall St. Rank hold HOWL as of Q3 2025.

  • Essential Partners reported no remaining Werewolf Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Essential Partners sold 52 Werewolf Therapeutics shares in Q3 2025, an estimated $57.
  • Essential Partners first reported a position in Werewolf Therapeutics in Q2 2025 and held it in 1 quarter.
  • Essential Partners's Werewolf Therapeutics position peaked at $57 in Q2 2025.
  • 62 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.